InterValve Inc. said on Wednesday it received an undisclosed investment from local group Twin Cities Angels II. The funding moves the Minnetonka-based medical device firm closer to its goal of raising $7.5 million in its latest investment round, said CEO Mark Ungs. InterValve is developing a medical device that will help treat patients with aortic stenosis, a condition when the heart’s aortic valve does not fully open. Patients with aortic stenosis can undergo surgery to input a new valve or choose a less invasive, more expensive procedure recently approved by the U.S. Food and Drug Administration, where a new valve is snaked through a patient’s groin area to their heart.
